Exhibit 5.2
| | |
 | | Linklaters LLP World Trade Centre Amsterdam Zuidplein 180 1077 XV Amsterdam Telephone (31 20) 799 6200 Facsimile (31 20) 799 6300 |
Thermo Fisher Scientific (Finance I) B.V.
Takkebijsters 1
4817 BL Breda
The Netherlands
18 November 2021
Dear Sirs
Thermo Fisher Scientific (Finance I) B.V. (the “Company”) – €1,700,000,000 Floating Rate Senior Notes due 2023, €550,000,000 0.000% Senior Notes due 2023 and €550,000,000 0.000% Senior Notes due 2025 (collectively, the “Securities”) guaranteed by Thermo Fisher Scientific Inc.
1 | We have acted as your Dutch legal advisers in connection with the Form S-3 registration statement filed with the United States Securities and Exchange Commission on 28 February 2019 (the “Registration Statement”) relating to the registration (the “Registration”) under the United States Securities Act of 1933 (as amended) (the “Securities Act”) of, inter alia, debt securities of the Company, and the issuance by the Company of the Securities, which are stated to be irrevocably and unconditionally guaranteed as to payment of principal, premium, if any, and interest by Thermo Fisher Scientific Inc. (the “Guarantor”), a Delaware corporation. The Securities are being issued pursuant to the Indenture (as defined in the Schedule to this letter). We have taken instructions solely from the Company. |
2 | This opinion is limited to Dutch law as applied by the Dutch courts and published in print and in effect on the date of this opinion, excluding tax law, the laws of the European Union (insofar as not implemented or incorporated in Dutch law) and market abuse, competition and procurement laws. This opinion is given on the basis that we undertake no responsibility to notify any addressee of this opinion of any change in Dutch law after the date of this opinion. It is given in accordance with customary Dutch legal practice and on the basis that it and all matters relating to it will be governed by and construed in accordance with Dutch law. In this opinion, Dutch legal concepts are expressed in English terms and not in their original Dutch terms. The Dutch concepts concerned may not be identical to the concepts described by the English terms as they may exist or be interpreted under the laws of jurisdictions other than the Netherlands. |
3 | For the purpose of this opinion we have examined the documents listed and, where appropriate, defined (together with certain other terms used herein) in the Schedule to this letter. Our examination has been limited to the text of the documents. In addition we have obtained the following confirmations given by telephone or otherwise on 17 November 2021 (noting that we |
This communication is confidential and may be privileged or otherwise protected by work product immunity.
Linklaters LLP is a limited liability partnership registered in England and Wales with registered number OC326345. It is a law firm authorised and regulated by the Solicitors Regulation Authority. The term partner in relation to Linklaters LLP is used to refer to a member of Linklaters LLP or an employee or consultant of Linklaters LLP or any of its affiliated firms or entities with equivalent standing and qualifications. A list of the names of the members of Linklaters LLP together with a list of those non-members who are designated as partners and their professional qualifications is open to inspection at its registered office, One Silk Street, London EC2Y 8HQ, England or on www.linklaters.com and such persons are either solicitors, registered foreign lawyers or European lawyers. Linklaters LLP is also registered with the Dutch Trade Register of the Chamber of Commerce under number 34367130.
Please refer to www.linklaters.com/regulation for important information on our regulatory position.